MiR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation

Leukemia

Volumn 27, Issue 2, 2013, Pages 344-352

  Lin, X ^a   Rice, K L ^a   Buzzai, M ^b   Hexner, E ^c   Costa, F F ^d   Kilpivaara, O ^e   Mullally, A ^f   Soares, M B ^d   Ebert, B L ^f   Levine, R ^e   Licht, J D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Novartis   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; MICRORNA; MICRORNA 134; MICRORNA 214; MICRORNA 433; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CHROMATIN; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROPOIESIS; EX VIVO STUDY; GENE SILENCING; GENETIC ANALYSIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN MODIFICATION; PUBLICATION; THROMBOCYTHEMIA; VIRAL GENE DELIVERY SYSTEM;

ANTIGENS, CD34; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; ERYTHROID CELLS; ERYTHROPOIESIS; GENE EXPRESSION PROFILING; GTP-BINDING PROTEINS; HUMANS; JANUS KINASE 2; LUCIFERASES; MICRORNAS; MUTATION; MYELOPROLIFERATIVE DISORDERS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84873570369     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.224     Document Type: Article

References (38)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372-375.
2. Gilliland DG, Blanchard KL, Levy J, Perrin S, Bunn HF. Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction. Proc Natl Acad Sci USA 1991; 88: 6848-6852.
3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
5. Cario H, Goerttler PS, Steimle C, Levine RL, Pahl HL. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol 2005; 130: 800-801.
6. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108: 346-352.
7. Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375-379.
8. Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 2010; 115: 2882-2890.
9. Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood 2006; 108: 3646-3653.
10. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005; 15: 563-568.
11. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006; 66: 7390-7394.
12. Georgantas 3rd RW, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S et al. CD34\+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104: 2750-2755.
13. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exper Hematol 2007; 35: 1657-1667.
14. Bruchova H, Merkerova M, Prchal JT. Aberrant expression of microRNA in polycythemia vera. Haematologica 2008; 93: 1009-1016.
15. Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34\+ cells. Blood 2007; 109: 4399-4405.
16. Guglielmelli P, Tozzi L, Bogani C, Iacobucci I, Ponziani V, Martinelli G et al. Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. Blood 2011; 117: 6923-6927.
17. Gorbacheva VY, Lindner D, Sen GC, Vestal DJ. The interferon (IFN)-induced GTPase, mGBP-2. Role in IFN-gamma-induced murine fibroblast proliferation. J Biol Chem 2002; 277: 6080-6087.
18. Guo S, Lu J, Schlanger R, Zhang H, Wang JY, Fox MC et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci USA 2010; 107: 14229-14234.
19. Kong KY, Owens KS, Rogers JH, Mullenix J, Velu CS, Grimes HL et al. MIR-23A microRNA cluster inhibits B-cell development. Exper Hematol 2010; 38: 629-640, e621.
20. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD et al. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114: 3872-3879.
21. Slezak S, Jin P, Caruccio L, Ren J, Bennett M, Zia N et al. Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and-133a. J Transl Med 2009; 7: 39.
22. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114: 5331-5341.
23. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exper Med 2008; 205: 585-594.
24. Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010; 17: 584-596.
25. Luo H, Zhang H, Zhang Z, Zhang X, Ning B, Guo J et al. Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exper Clin Cancer Res 2009; 28: 82.
26. Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis 2012; 33: 1113-1120.
27. Furlong F, Prencipe M, McGoldrick A, McGettigan P, Carney D, Doyle E et al. miR-433 overexpression attenuates the spindle assembly checkpoint response to paclitaxel. Breast Cancer Res 2010; 12: S11-S11.
28. Novershtern N, Subramanian A, Lawton LN, Mak RH, Haining WN, McConkey ME et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 2011; 144: 296-309.
29. Vestal DJ. The guanylate-binding proteins (GBPs): proinflammatory cytokineinduced members of the dynamin superfamily with unique GTPase activity. J Interferon Cytokine Res 2005; 25: 435-443.
30. Balasubramanian S, Fan M, Messmer-Blust AF, Yang CH, Trendel JA, Jeyaratnam JA et al. The interferon-gamma-induced GTPase, mGBP-2, inhibits tumor necrosis factor alpha (TNF-alpha) induction of matrix metalloproteinase-9 (MMP-9) by inhibiting NF-kappaB and Rac protein. J Biol Chem 2011; 286: 20054-20064.
31. Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, Ponziani V et al. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exper Hematol 2007; 35: 1708-1718.
32. Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A, Vainchenker W et al. miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 2010; 116: 437-445.
33. Hussein K, Dralle W, Theophile K, Kreipe H, Bock O. Megakaryocytic expression of miRNA 10a, 17-5p, 20a and 126 in Philadelphia chromosome-negative myeloproliferative neoplasm. Ann Hematol 2009; 88: 325-332.
34. Pulikkan JA, Peramangalam PS, Dengler V, Ho PA, Preudhomme C, Meshinchi S et al. C/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood 2010; 116: 5638-5649.
35. Rice KL, Lin X, Wolniak K, Ebert BL, Berkofsky-Fessler W, Buzzai M et al. Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J 2011; 1: e40.
36. Bortoluzzi S, Bisognin A, Biasolo M, Guglielmelli P, Biamonte F, Norfo R et al. Characterisation and discovery of novel miRNAs and moRNAs in JAK2V617F mutated SET2 cells. Blood 2012; 119: e120-30.
37. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 2009; 296: E22-36.
38. Guimaraes DP, Oliveira IM, de Moraes E, Paiva GR, Souza DM, Barnas C et al. Interferon-inducible guanylate binding protein (GBP)-2: a novel p53-regulated tumor marker in esophageal squamous cell carcinomas. Int J Cancer 2009; 124: 272-279.